Sanaria
Sanaria

WELCOME TO SANARIA

Sanaria is a biotechnology company exclusively dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Sanaria’s vaccine is based on an approach to immunization that has already proven highly protective in humans.
Learn more

Plasmodium falciparum malaria is responsible for more childhood mortality than any other single infectious agent. Sanaria’s vaccine development efforts are focused on African children, the population most urgently in need of protection. Annually, malaria is responsible for more than 100 million cases and 1 million deaths among African infants and children. Globally there are additional unmet medical needs of enormous proportions, and multiple potential markets.
Learn more

Sanaria is a Maryland-based company that is continually seeking motivated staff and investors with a passion to engage in the fight against malaria.
Learn more

Sanaria

Sanaria named Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration.


Learn more

Sanaria


Sanaria

Sanaria opens new Clinical Manufacturing Facility.


Learn more

 

Sanaria

July 2008
Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant; Press Release

May 2008
Sanaria named Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration; Tech Council of Maryland;
Press Release; Gazette.net

March 2008
Sanaria featured in Scientific American; Scientific American

January 2008
Sanaria enters into $23.6 million research agreement; Press Release

December 2007
Sanaria featured in The New York Times, The Soul of a New Vaccine; and accompanying video, Searching for a Cure for Malaria

December 2007
Q & A Session with Sanaria: How to bring a malaria vaccine to market? Larta Institute

December 2007
Sanaria CEO, Dr. Stephen L. Hoffman, interviewed on Al Jazeera English's: The Pulse

November 2007
Sanaria announced that Adel A. F. Mahmoud, M.D., Ph.D, of the Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University and former President of Merck Vaccines, was elected to Sanaria's Board of Directors

October 2007
Sanaria opens Clinical Manufacturing Facility; Press Release: featured in Reuters

October 2007
Fred Binka (Sanaria Advisory Board Memeber) featured in Newsweek,
"Giving Globally: The Search for Solutions"

July 2007
Sanaria featured in National Geographic magazine, Bedlam in the Blood, Malaria

April 2007
Sanaria featured in BBC documentary.

 

disclaimer     site map

copyright(c) 2003-2008, Sanaria Inc., all rights reserved
website design by cymaxmedia.com